文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

病毒学抑制经治HIV患者中存档M184V突变的动力学

Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PubMed 文献 · J Infect Dis · 2022-01-01

该研究对79例HIV RNA持续低于50拷贝/mL至少5年且既往RNA中记录M184V突变的经治患者,比较2016与2019年储存血细胞HIV DNA的Sanger和超深度测序。联合测序显示33%患者M184V缺失、67%持续存在;37例超深度测序者中M184V阳性耐药变异比例从40%降至14%(P=.005)。M184V持续与3TC/FTC暴露下HIV RNA复制时长和水平相关。

要点

  • 联合Sanger和超深度测序,67%(53/79)长期病毒学抑制患者HIV DNA中M184V持续存在。
  • 37例超深度测序患者中M184V阳性耐药变异比例从2016年40%降至2019年14%(P=.005)。
  • M184V持续与3TC/FTC暴露下HIV RNA复制时长(P=.0009)和水平(P=.009)相关。

核心结论

  • HIV DNA中M184V突变随时间减少,但在既往3TC/FTC暴露下复制更久、治疗经历更多的患者中更常持续存在。

研究设计与样本

  • 对2016年和2019年储存的血细胞HIV DNA进行Sanger和超深度测序(检测阈值1%)。
  • 纳入79例接受ART、HIV RNA低于50拷贝/mL至少5年且既往HIV RNA中记录M184V突变的患者。

主要发现

  • 联合Sanger和超深度测序,26/79(33%)患者M184V缺失,53/79(67%)持续存在。
  • M184V阳性患者有更长ART史、更低CD4最低值和更高治疗前HIV RNA。
  • 37例超深度测序患者中,M184V阳性耐药变异比例从2016年40%降至2019年14%(P=.005)。
  • M184V持续与3TC/FTC暴露下HIV RNA复制时长(P=.0009)和水平(P=.009)相关。

临床怎么用

  • 对长期病毒学抑制的经治患者,既往M184V可能存留于HIV DNA,解读耐药存档时需结合3TC/FTC暴露史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to assess the kinetics of drug-resistant viral variants (DRVs) harboring the M184V mutation in proviral DNA of long-term virally suppressed patients, and factors associated with DRV persistence. METHODS: Human immunodeficiency virus (HIV) DNA from blood cells stored in 2016 and 2019 was sequenced using Sanger and ultradeep sequencing (SS and UDS; detection threshold 1%) in antiretroviral therapy (ART)-treated patients with HIV RNA < 50 copies/mL for at least 5 years, with past M184V mutation documented in HIV RNA. RESULTS: Among 79 patients, by combining SS and UDS, M184V was found to be absent in 26/79 (33%) patients and persistent in 53/79 (67%). M184V-positive patients had a longer history of ART, lower CD4 nadir, and higher pretherapeutic HIV RNA. Among 37 patients with viral sequences assessed by UDS, the proportion of M184V-positive DRVs significantly decreased between 2016 and 2019 (40% vs 14%, P = .005). The persistence of M184V was associated with duration and level of HIV RNA replication under lamivudine/emtricitabine (3TC/FTC; P = .0009 and P = .009, respectively). CONCLUSIONS: While it decreased over time in HIV DNA, M184V mutation was more frequently persistent in HIV DNA of more treatment-experienced patients with longer past replication under 3TC/FTC.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Palich R, Teyssou E, Sayon S, et al. Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients. J Infect Dis. 2022. PMID: 34415048. doi:10.1093/infdis/jiab413

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。